Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Show more
30 Technology Drive, Warren, NJ, 07059, United States
Start AI Chat
Market Cap
484.4M
52 Wk Range
$2.12 - $7.55
Previous Close
$3.97
Open
$3.97
Volume
2,433,174
Day Range
$3.89 - $4.10
Enterprise Value
677.7M
Cash
129.1M
Avg Qtr Burn
-12.65M
Insider Ownership
3.37%
Institutional Own.
62.06%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
SUBOXONE (buprenorphine/naloxone) Details Opioid addiction | Approved Quarterly sales | |
Exservan™ (riluzole) Oral Film Details Amyotrophic Lateral Sclerosis (ALS) | Approved Quarterly sales | |
Approved Quarterly sales | ||
KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details Parkinson’s disease (OFF Episodes / motor fluctuations) | Approved Quarterly sales | |
ZUPLENZ (ondansetron) Details Nausea and vomiting | Approved Quarterly sales | |
NDA Resubmission | ||
AQST-108 (epinephrine) Topical Gel Details Alopecia areata | IND Submission | |
AQST-119 Details Erectile dysfunction
| Failed Discontinued |
